Drug intelligence / Profile preview

TheraCeed

Development stage: Unknown
Lead developer: The Cannabist Company
Administration: Inhalation, Oral, Sublingual, Topical

Overview

TheraCeed is a branded medical cannabis product line developed and marketed by Columbia Care through Cannabist. It comprises cannabis-derived formulations containing tetrahydrocannabinol and cannabidiol, commonly in a 20:1 THC:CBD ratio, and is offered in multiple dosage forms including tablets, capsules, sublingual tinctures, and vape cartridges. Its pharmacology is mediated through cannabinoids acting on the endocannabinoid system, primarily via cannabinoid receptors, to provide symptomatic relief for conditions such as severe pain, muscle spasms, nausea, vomiting, appetite loss, and sleep disturbance in jurisdictions where medical cannabis is legally dispensed.

Brand names: TheraCeed

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on TheraCeed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraCeed.

Explore the full profile